Transave, Inc.'s SLIT™ Amikacin Is Granted Orphan Drug Designation By The European Commission For The Treatment Of Pseudomonas Aeruginosa Lung Infections In Cystic Fibrosis

Transave, Inc., a biopharmaceutical company focused on the development of inhaled, liposomal formulation of drugs for treating life threatening lung diseases, today announced that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted SLIT™ Amikacin orphan drug status for the treatment of Pseudomonas aeruginosa (Pa) lung infections in cystic fibrosis (CF).